Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Related Citations for PubMed (Select 23324437)

1.

Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients.

Zheng F, Yin X, Lu W, Zhou J, Yuan H, Li H.

J Endocrinol Invest. 2013 Jul-Aug;36(7):489-96. doi: 10.3275/8811. Epub 2013 Jan 14.

PMID:
23324437
2.

Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.

Zhou J, Li H, Zhang X, Peng Y, Mo Y, Bao Y, Jia W.

Diabetes Technol Ther. 2013 Jun;15(6):481-8. doi: 10.1089/dia.2013.0046. Epub 2013 Apr 30.

3.

Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.

Kim MK, Suk JH, Kwon MJ, Chung HS, Yoon CS, Jun HJ, Ko JH, Kim TK, Lee SH, Oh MK, Rhee BD, Park JH.

Diabetes Res Clin Pract. 2011 Jun;92(3):322-8. doi: 10.1016/j.diabres.2011.01.022. Epub 2011 Mar 3.

PMID:
21376417
4.

Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.

Gao HW, Xie C, Wang HN, Lin YJ, Hong TP.

Acta Pharmacol Sin. 2007 Apr;28(4):534-9.

5.
6.
7.

Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.

Abrahamian H, Francesconi M, Loiskandl A, Dzien A, Prager R, Weitgasser R.

Diabetes Technol Ther. 2004 Feb;6(1):31-7.

PMID:
15000767
8.

Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.

Kato T, Inoue T, Node K.

Cardiovasc Diabetol. 2010 Mar 24;9:12. doi: 10.1186/1475-2840-9-12.

9.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
10.

[A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus].

Pan CY, Gao Y, Li GW, Zhu XX, Gao X, Liu X.

Zhonghua Nei Ke Za Zhi. 2009 Apr;48(4):304-7. Chinese.

PMID:
19576120
11.

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

Diabetes Care. 2001 Jun;24(6):983-8.

PMID:
11375357
12.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
13.

Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.

Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR.

Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):484-90.

PMID:
12469362
14.

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

Hanefeld M, Bouter KP, Dickinson S, Guitard C.

Diabetes Care. 2000 Feb;23(2):202-7.

15.

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

Hirschberg Y, Karara AH, Pietri AO, McLeod JF.

Diabetes Care. 2000 Mar;23(3):349-53.

16.

Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.

Hazama Y, Matsuhisa M, Ohtoshi K, Gorogawa S, Kato K, Kawamori D, Yoshiuchi K, Nakamura Y, Shiraiwa T, Kaneto H, Yamasaki Y, Hori M.

Diabetes Res Clin Pract. 2006 Mar;71(3):251-5. Epub 2005 Oct 7.

PMID:
16214255
17.

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.

Diabetes Care. 2000 Nov;23(11):1660-5.

18.

Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.

Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D.

J Clin Endocrinol Metab. 2002 Sep;87(9):4171-6.

PMID:
12213867
19.

A review of nateglinide in the management of patients with type 2 diabetes.

Tentolouris N, Voulgari C, Katsilambros N.

Vasc Health Risk Manag. 2007;3(6):797-807. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk